Breaking News!

Adopting Consensus Terms for Testing in Precision MedicineAASCO Journal of Clinical Oncology

"Despite the well-understood benefits of biomarker and genetic testing in precision medicine, uptake remains low, particularly for patients with low socioeconomic status and minority ethnic backgrounds... A LUNGevity Foundation... assessed and recommended specific terms for communicating with patients on testing for tumor characteristics and germline mutations. Read this article

ICAN Co-authors Letter on COVID-19 Intellectual Property Waiver

"Waiving intellectual property rights on COVID-19 vaccines initially sounds good, but is a threat to the drug discovery pipeline that cancer patients and all patients depend on."
— Marcia K. Horn, ICAN CEO and Exon 20 Group Executive Director   Read the letter

First Exon 20 Drug Approved!

"Congratulations to Janssen Oncology and its principal investigators and study teams as well as to amivantamab patients and their families throughout the Exon 20 Group."
— Marcia K. Horn, ICAN CEO and Exon 20 Group Executive Director   Full article here!

Exon 20 Group Members Acknowledged!

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

"The authors wish to thank the patients, families, and caregivers involved in the clinical trial as well as the Exon 20 Group, Marcia Horn, Robert Hanlon, and Kevin Hanlon."
—See article at cell.com/cancer-cell


A visual exploration of data presented at ASCO 2021 Virtual Meeting

A visual exploration of data presented at ASCO 2021 Virtual Meeting- Video(mp4) LARVOL VERI

Patient Advocate Comment: Amivantamab for Exon 20 by Marcia K. Horn JD— IASLC News

ICAN CEO, Marcia Horn, Quoted in Precision Oncology News on the COVID-19 Crisis: Precision Oncology Programs Adapting to Ensure Patient Safety, Care During Public Health Crisis.


PROs--Patient Reported Outcomes--are a big priority for ICAN

Please take a look at this article, co-authored by ICAN's CEO Marcia Horn along with a group of her favorite research advocates.

Including the patient voice in the development and implementation of patient‐reported outcomes in cancer clinical trials more...

ICAN Celebrates MDRT Foundation Grant –

Stephen Rothschild (far right) presents MDRT Foundation check to ICAN Leadership.
From Left: ICAN CEO Marcia Horn, Josefine and David Perry, 2018 ICAN Liberty Mutual Invitational Tournament Chair and Reception Host Cathy Dalzell, Tournament Chair Wendy Look, Tournament Chair Michael Friedman, and Reception Honorees, Debbie and Steve Rothschild. more...

TRK Fusion Webinar

ICAN, because of our deep involvement with rare cancers and our interest in integrating the patient and caregiver voice in clinical research, is proud to have sponsored a special webinar on TRK Fusion Cancers.

The webinar took place on Monday and is now available on YouTube.

Watch Now

ICAN in the Dominican Republic

group photo
Professor Fernando Ferrer (left) and INCART's Dr Adrian Puello Guerrero

Forging Relationships with Dominican Cancer Experts. Read the full article here.

ICAN Hispanic and Ibero-American Council President, Professor Fernando Ferrer MBA, visited Dominican Republic at the end of January and presented a series of conferences at various...

Read more

ICAN's Exon 20 Group Raises $25,000 for Broad Institute of MIT

group photo
From left: Robert T. Hanlon, Heidi Greulich and Bethany Kaplan

Swing Fore Life Golf Invitational $25,000 Grant Presented to Broad Institute of MIT

Robert T. Hanlon, PhD, Exon 20 Group Co-Founder and Chair, presented a check for the $25,000 proceeds from the Swing Fore Life Golf Invitational to Heidi Greulich, PhD, Senior Group Leader in the Cancer Program at The Broad Institute of MIT and Harvard. 

Together with Dr. Matthew Meyerson, Dr. Greulich is leading a group at the Broad Institute studying therapeutic approaches to treating cancers...

Read more

Scott Khan and Fernando Ferrer

Scott Khan, PhD – Chairman, ICAN Biomarkers Council and Fernando Ferrer, MBA  Chairman, ICAN Hispanic and Ibero-American Communities Council– at BioNJ Patient Advocacy Summit.

Colorado Governor signs bill

Annie Achee, member of ICAN's National Board (on the Governor's left in the black suit), is present as Colorado Governor Hickenlooper signs the biosimilars prescriber communication law. Annie and her husband, Colorado radiologist Dr. Mitch Achee, worked tirelessly to help pass this important patient safety law. Mitch, also a member of ICAN's National Board, provided compelling testimony to the Colorado legislature along with ICAN National Board members Frank Ramirez and Paul Thompson.

Guidestar Platinum Seal of Transparency 2021

Federal Tax I.D.: EIN 86-0818253